LQDA250117P17500
- 5.30
- 0.000.00%
Liquidia Newsroom
Liquidia Analyst Ratings
Liquidia Technologies: Buy Rating Driven by Yutrepia's FDA Approval Potential and Market Expansion
Needham Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $19
Analysts Are Bullish on Top Healthcare Stocks: Surgery Partners (SGRY), Liquidia Technologies (LQDA)
BTIG Maintains Liquidia(LQDA.US) With Buy Rating, Raises Target Price to $29
Wells Fargo Initiates Liquidia(LQDA.US) With Buy Rating, Announces Target Price $20
Wells Fargo Initiates Coverage on Liquidia With Overweight Rating, $20 Price Target
HC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $29 Price Target
Scotiabank Maintains Liquidia(LQDA.US) With Buy Rating, Raises Target Price to $30
A Quick Look at Today's Ratings for Liquidia(LQDA.US), With a Forecast Between $19 to $31
Liquidia Technologies (LQDA) Gets a Buy From Scotiabank
Liquidia Analyst Ratings
Liquidia Technologies: Strategic Advancements and Legal Win Bolster Buy Rating
Liquidia Analyst Ratings
Scotiabank Initiates Liquidia at Sector Outperform With $30 Price Target
LifeSci Capital Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $30
Raymond James Maintains Liquidia(LQDA.US) With Buy Rating
BTIG Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $25
LifeSci Capital Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $30
Buy Rating Affirmed for Liquidia Technologies Following Positive Legal Developments for Yutrepia